**SDC, Table 1:** Search strategy

|  |  |
| --- | --- |
| Database | Search strategy |
| PubMed | ("Breast Neoplasms"[Mesh] OR "Genital Neoplasms, Female"[Mesh] OR ((Cancer\*[Tiab] OR tumor[Tiab] OR tumors[tiab] OR tumour\*[Tiab] OR carcino\*[Tiab] OR neoplasm\*[Tiab] OR sarcom\*[Tiab] OR malignan\*[Tiab]) AND (breast[Tiab] OR genital[Tiab] OR fallopian[Tiab] OR vagina\*[Tiab] OR vulvar[Tiab] OR vulval[Tiab] OR ovarian[Tiab] OR ovary[Tiab] OR uterus[Tiab] OR uterine[Tiab] OR endometri\*[Tiab] OR gynecologic\*[Tiab] OR gynaecologic\*[Tiab]))) AND (Mindfulness[Mesh] OR Meditation[Mesh] OR Mindfulness[tiab] OR meditation[tiab] OR mbsr[tiab] OR mbct[tiab] OR mbcr[tiab]) |

**SDC, Table 2:** Reasons for dropping out from a study (control groups)

| Authors |  | Year | Reasons for dropping out from a study (control groups) |
| --- | --- | --- | --- |
| Tacon *et al.40* |  | 2004 | n/a |
| Tacon *et al.39* |  | 2006 | n/a |
| Witek *et al.23* |  | 2008 | Did not want additional phlebotomies  Started different stress reduction program  Failed follow-up meetings |
| Matousek *et al.24* |  | 2010 | n/a |
| Lengacher *et al.25* |  | 2011 | n/a |
| Matchim *et al.26* |  | 2011 | Travel  Disease  Schedule conflicts |
| Tacon *et al.27* |  | 2011 | n/a |
| Henderson *et al.18* |  | 2012 | n/a |
| Hoffman *et al.28* |  | 2012 | Illness other than BC  Moved away  Cumbersome questionnaire  Deceased |
| Carlson *et al.19* |  | 2013 | n/r |
| Stafford *et al.29* |  | 2013 | n/a |
| Würtzen *et al. 41* |  | 2013 | n/a |
| Eyles *et al.30* |  | 2015 | n/a |
| Johannsen *et al.31* |  | 2016 | Refusal to be on the waitlist  Death in family |
| Bisseling *et al.32* |  | 2017 | n/a |
| Chung *et al.33* |  | 2017 | Diagnosis of secondary malignancy  Refusal of follow-up assessment |
| Kenne *et al.20* |  | 2017 | n/r |
| Norouzi *et al.34* |  | 2017 | Study withdrawal  Health problems |
| Pintado *et al.21* |  | 2017 | n/r |
| Vaziri *et al.35* |  | 2017 | n/a |
| Zhang *et al.36* |  | 2017 | n/a |
| Park *et al.37* |  | 2018 | n/a |
| Witek *et al.22* |  | 2019 | Started chemotherapy  Moved away  Other illness  Too busy |
| Zhang *et al.42* |  | 2019 | n/a |
| Elimimian *et al.38* |  | 2020 | n/a |

n/a: not applicable for pre-post design

n/r: not reported

**SDC, Table 3:** Study participation data

| Authors | Year | Number assessed for eligibility | Number ineligible (reasons) | Number eligible | Reasons for refusing to take part in an MBI study | Study participation rate in % | Study completion rate in % |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Tacon *et al.40* | 2004 | n/rh | n/r | n/r | n/r | n/r | n/r |
| Tacon *et al.39* | 2006 | n/rh | n/r | n/r | n/r | n/r | n/r |
| Witek *et al.23* | 2008 | n/r | n/r | n/r | n/r | n/r | n/r |
| Matousek *et al.24* | 2010 | 63 | 1 (n/r) | 62 | n/r | 98.4 | 93.5 |
| Lengacher *et al.25* | 2011 | n/r | n/r | 58 | Organizational challenges; travel distance; lack of interest; health-related problems | 32.8 | 89.5 |
| Matchim *et al.26* | 2011 | n/r | n/r | n/r | n/r | n/r | 88.9 |
| Tacon *et al.27* | 2011 | n/rh | n/r | n/r | n/r | n/r | 89.2 |
| Henderson *et al.18* | 2012 | n/r | n/r | 199 | n/r | 90.4 | n/r |
| Hoffman *et al.28* | 2012 | 643h | n/ra | n/r | Organizational challenges; travel distance; health-related problems | n/r | 93.4 |
| Carlson *et al.19* | 2013 | 956h | 271e (< Distress criteria; current adjuvant ttt; previously completed an MBCR program; autoimmune disease; axis I psychological disorder; metastatic (stage IV)/non–breast cancer; suicidal thoughts; language; other) | 429-685f | Organizational challenges; travel distance;  lack of interest; did not want to be randomly assigned; did not want to give blood samples | n/rg | 67.9 |
| Stafford *et al.29* | 2013 | 105 | n=23 (not currently receiving treatment/on active follow-up) | 82 | Organizational challenges; travel distance; lack of interest; health-related problems; too important commitment; not convenient | 64.6 | 67.9 |
| Würtzen *et al. 41* | 2013 | n/r | n/r | 1208 | n/r | 27.8 | 84.2 |
| Eyles *et al.30* | 2015 | 100h | n=80 (n=27 unspecified; n=19 too ill; n=13 commitment) | 81 or 72b | Organizational challenges; travel distance; health-related problems; too important commitment | 24.6 or 27.8b | 95 |
| Johannsen *et al.31* | 2016 | 1546 | n=1303 (n=1162: pain ≤2; n=61: no valid pain assessment; n=9: no reason) | 314 | Organizational challenges; travel distance; lack of interest; health-related problems | 41.1 | 74.4 |
| Bisseling *et al.32* | 2017 | 90h | n=1 (ovarian cancer) | 89 | Organizational challenges; travel distance; lack of interest; reluctance to face other patients; participation in other psychological intervention | 71.9 | 81.3 |
| Chung *et al.33* | 2017 | 72 | n=6 (early stage) | 64-66c | n/r | 48-50.0c | 56.3 |
| Kenne *et al.20* | 2017 | n/r | n/r | n/r | n/r | n/r | 93.8 |
| Norouzi *et al.34* | 2017 | n/r | n/r | n/r | n/r | n/r | 83.8 |
| Pintado *et al.21* | 2017 | n/r | n/r | 35 | Organizational challenges; | 82.9 | n/r |
| Vaziri *et al.35* | 2017 | 100h | n/r | 37 | n/r | 54.1 | 80.0 |
| Zhang *et al.36* | 2017 | 122 | n=3 (stage IV, other cancer) | 119 | Organizational challenges; travel distance; lack of interest; | 50.4 | 96.7 |
| Park *et al.37* | 2018 | 50 | n=1d (stage IV) | 49 | Organizational challenges; lack of interest | 26.5 | 92.3 |
| Witek *et al.22* | 2019 | 1055 | n=540 (n/r) | 515 | n/r | 37.3 | 64.6 |
| Zhang *et al.42* | 2019 | 2022 | n=1552 (n/r) | 470 | n/r | 14.9 | 85.7 |
| Elimimian *et al.38* | 2020 | n/r | n/r | n/r | n/r | n/r | 35.1 |

Study participation rate (SPR) = numbers included (randomized and non-randomized) in study X 100/numbers eligible for the study17

Study completion rate (SCR) = numbers completed (all groups) study X 100/numbers included in the study17

n/r = *data not reported* or *unclear data* or *not calculable* based on data reported

n/a = *not applicable*

a Flow diagram unclear (eligible, not eligible/declined 🡪 SPR could not be calculated; n=2 missing in the flow diagram)

b Unclear if “treatment issues” was an eligibility criterion. SPR calculation depends on the number eligible

c n=2 missing in the participation flow diagram

d Incomplete information (nb ineligible)

e Number composed of ineligible (271) + declined (152) + unknown (256)

f 429 (271 + 152 + 6) ±256 without reason recorded

g Unclear because 256 excluded/ineligible without reasons

h Eligible number not clear (e.g. different definitions, eligibility assessed in several stages, possible previous sorting not documented, unclear if those who declined were eligible or not)